维亚生物(01873)于新公告中披露，将在即将召开的股东周年大会上，向董事授予一般授权以购回公司股份，规模最高可达公司已发行股本总面值的10%。上述授权若获通过，董事会可于香港联合交易所有限公司（联交所）或其他获认可的证券交易所进行股份回购。
维亚生物公告显示，董事会认为回购股份有助于在适当时提升每股净资产值和/或每股盈利，符合公司及整体股东的最大利益。购回资金将由公司可合法动用的营运资金或现金流拨付，并遵照上市规则及开曼群岛相关法律进行操作。
据公告，维亚生物股东周年大会订于2026年6月26日举行，届时将提呈该项股份购回授权议案。公司同时提醒股东，将于6月23日至6月26日暂停办理股份过户登记，以确定具有投票资格的股东名册。若该购回授权获得批准，将一直有效至下届股东周年大会结束或其他相关期限届满为止。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.